Cinryze® (C1 esterase inhibitor [human]) – Expanded indication
June 21, 2018 - Shire announced the FDA approval of Cinryze (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (≥ 6 years old) with hereditary angioedema (HAE).
Top